News
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...
Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results